Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Trial Profile

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Apixaban (Primary) ; Warfarin
  • Indications Atrial fibrillation
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jul 2017 Trial design published in the Clinical Cardiology
    • 27 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 10 Mar 2017 Planned End Date changed from 1 Oct 2016 to 5 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top